We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Impax Laboratories, Inc. (delisted) | NASDAQ:IPXL | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 18.30 | 18.30 | 18.55 | 0 | 01:00:00 |
Delaware
|
|
65-0403311
|
(State or other jurisdiction of
incorporation or organization) |
|
(I.R.S. Employer
Identification No.) |
30831 Huntwood Avenue
Hayward, CA
|
|
94544
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Bryan M. Reasons
Chief Financial Officer and
Sr. Vice President, Finance
Impax Laboratories, Inc.
30831 Huntwood Avenue
Hayward, CA 94544
(510) 240-6000
|
Copy To:
Tad J. Freese, Esq.
Latham & Watkins LLP 140 Scott Drive Menlo Park, California 94025 (650) 328-4600 |
Large Accelerated Filer ☒
|
Accelerated Filer ☐
|
Non-Accelerated Filer ☐ (Do not check if a smaller reporting company)
|
Smaller Reporting Company ☐
|
|
Emerging Growth Company ☐
|
Title of securities
to be registered
|
Amount
to be registered (1) |
Proposed
maximum offering price per share |
Proposed
maximum aggregate offering price |
Amount of
registration fee |
Common Stock, $0.01 Par Value
|
100,000
(2)
|
$18.18
(3)
|
$1,818,000
3)
|
$211
|
(1)
|
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “
Securities Act
”), this registration statement shall also cover any additional shares of the registrant’s common stock, par value $0.01 per share (the “
Common Stock
”), that become issuable under the plan by reason of any stock dividend, stock split, recapitalization or similar transaction effected without the registrant’s receipt of consideration which would increase the number of outstanding shares of Common Stock.
|
(2)
|
Represents 100,000 additional shares of Common Stock reserved and authorized for issuance under the Impax Laboratories, Inc. Amended and Restated Non-Qualified Employee Stock Purchase Plan (the “
Plan
”).
|
(3)
|
This estimate is made pursuant to Rule 457(c) and Rule 457(h) of the Securities Act solely for the purpose of calculating the registration fee for the securities registered hereunder based on the average of the high and low prices for the Common Stock as reported on The NASDAQ Global Select Market on August 24, 2017.
|
Item 3.
|
Incorporation of Documents by Reference
.
|
Item 4.
|
Description of Securities
.
|
Item 5.
|
Interests of Named Experts and Counsel
.
|
Item 6.
|
Indemnification of Directors and Officers
.
|
|
•
|
is or was a director, officer, employee or agent of such corporation; or
|
|
|
|
|
•
|
is or was serving at the request of such corporation as a director, officer, employee or agent of another corporation or other enterprise.
|
|
•
|
acted in good faith and in a manner such person reasonably believed to be in, or not opposed to, the best interests of the corporation; and
|
|
|
|
|
•
|
with respect to any criminal action or proceeding, had no reasonable cause to believe the person’s conduct was unlawful.
|
Item 7.
|
Exemption from Registration Claimed
.
|
Item 8.
|
Exhibits
.
|
Item 9.
|
Undertakings
.
|
|
IMPAX LABORATORIES, INC.
|
||
|
|
|
|
|
By:
|
/s/ Bryan M. Reasons
|
|
|
|
Name:
|
Bryan M. Reasons
|
|
|
Title:
|
Senior Vice President, Finance, and
|
|
|
|
Chief Financial Officer
|
Signature
|
|
Title
|
Date
|
|
|
|
|
/s/ Paul M. Bisaro
|
|
President, Chief Executive Officer and Director
|
August 29, 2017
|
Paul M. Bisaro
|
|
(Principal Executive Officer)
|
|
|
|
|
|
/s/ Bryan M. Reasons
Bryan M. Reasons |
|
Senior Vice President, Finance, and Chief Financial Officer (Principal Financial and Accounting Officer)
|
August 29, 2017
|
|
|
|
|
/s/Robert L. Burr
|
|
Chairman of the Board
|
August 29, 2017
|
Robert L. Burr
|
|
|
|
|
|
|
|
/s/ Leslie Z. Benet, Ph.D.
|
|
Director
|
August 29, 2017
|
Leslie Z. Benet, Ph.D.
|
|
|
|
|
|
|
|
______________
|
|
Director
|
August 29, 2017
|
Richard A. Bierly
|
|
|
|
/s/ J. Kevin Buchi
|
|
Director
|
August 29, 2017
|
J. Kevin Buchi
|
|
|
|
|
|
|
|
/s/Allen Chao, Ph.D.
|
|
Director
|
August 29, 2017
|
Allen Chao, Ph.D.
|
|
|
|
|
|
|
|
/s/ Mary K. Pendergast, J.D.
|
|
Director
|
August 29, 2017
|
Mary K. Pendergast, J.D.
|
|
|
|
|
|
|
|
/s/Peter R. Terreri
|
|
Director
|
August 29, 2017
|
Peter R. Terreri
|
|
|
|
|
|
|
|
/s/Janet S. Vergis
|
|
Director
|
August 29, 2017
|
Janet S. Vergis
|
|
|
|
Specimen of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Company’s Registration Statement on Form 10 (File No. 000-27354) filed with the SEC on October 10, 2008).
|
|
|
|
Impax Laboratories, Inc. Amended and Restated Non-Qualified Employee Stock Purchase Plan.
|
|
|
|
Opinion of Latham & Watkins LLP.
|
|
|
|
Consent of Latham & Watkins LLP (included in Exhibit 5.1).
|
|
|
|
Consent of KPMG LLP.
|
|
|
|
24.1
|
Power of Attorney (included in the signature page to this registration statement).
|
|
|
1 Year Impax Laboratories, Inc. (delisted) Chart |
1 Month Impax Laboratories, Inc. (delisted) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions